Otsuka Holdings News and Activities

Otsuka Holdings is one of the...

• Forbes Global 2000 (#654);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Otsuka Holdings is a company listed under the stock ticker 4578 (JP).

Otsuka Holdings has a direct presence in 11 countries.

Otsuka Holdings has 23 subsidiaries including Araris Biotech, Cambridge Isotope Laboratories and Interpharma.

They are in:

• Pharmaceuticals46%
• Medical Equipment29%
• Other25%

View the org chart displaying its 263 main executives

Most searched biographies at Otsuka Holdings

• Makoto Inoue, President and Representative Director, Chief Executi...
• Yukio Matsutani, Independent Director
• Jiro Seguchi, Outside Director and Board Member

Create your alert
to follow the executive moves at Otsuka Holdings.

Otsuka Holdings has 3,499 competitors including UnitedHealth Group (United States (USA)), Kaiser Permanente (United States (USA)) and HCA (United States (USA)).

Popular M&A news in Healthcare

• Adaptive Innovations has just announced a $50 Million fundraising (posted on June 4 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Freeman Health System has acquired Northwest Health (posted on June 2 2026).

Popular contacts in Healthcare

• Ari Bousbib - Chairman and Chief Executive Officer at IQVIA
• Gregory Adams - Chief Executive Officer and Chairman of the Board at Kaiser Permanente
• Pablo Legorreta - Chairman of the Board, Founder and Chief Executive Officer at Royalty Pharma

Learn more about the Healthcare industry

Press releases by Otsuka Holdings

• Otsuka Signs Joint Research Agreement with Keio UniversityIndustry-academia collaboration for infrastructure development toward the social implementation of psychedelics in Japan ｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Pharmavite Established a New Facility in Ohio, US, Dedicated to The Manufacturing of Gummy SupplementsFacilitating the Research and Development of Gummy Products｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Opens First POCARI SWEAT Factory in VietnamSupporting Health and Meeting Growing Demand｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical is Focusing on "Water, Nutrition, and Oxygen" to Tap into Human PotentialProvide "Wellness Energy" at Expo 2025 in Osaka, Kansai, Japan｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical is Expanding "Local Production and Local Recycling" of PET Bottle Initiatives in Cooperation with Local CommunitiesAgreement Signed with the Saga Eastern Environmental Facilities Association for Horizontal Recycling of PET Bottle｜New
• Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Is Now on Sale - Insurance coverage begins on March 1, 2025｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• Otsuka Pharmaceutical Finalizes an Agreement with Fukuroi City on the Horizontal Recycling of PET BottlesPartnering with Its Factory to Promote a "Local Production and Local Recycling" Initiative for PET Bottles｜News Releases | Otsuka Pharmaceutical Co.,
• Otsuka Sponsor TOKYO MARATHON 2025 Supporting the Conditioning of Runners Worldwide with the Global Brand POCARI SWEAT｜News Releases | Otsuka Pharmaceutical Co., Ltd.
• View more press releases Close

Social media about Otsuka Holdings

• Otsuka Holdings on Wikipedia, Google News & Yahoo Finance
• Otsuka Holdings on LinkedIn, X (Twitter) & YouTube